Keywords: Genzyme, Alemtuzumam, Sanofi-Aventis, Bayer, Campath, Multiple sclerosis, M&A
Positive Ph II five-year results with Genzyme’s alemtuzumab in MS patients could prompt higher bid from Sanofi, observers suggest
Article | 18 October 2010
US biotech major Genzyme Nasdaq: GEN), which is fending off an unsolicited takeover bid from France’s Sanofi-Aventis ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
